184 related articles for article (PubMed ID: 37019385)
21. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
Ko JM; Mayo TT; Bergfeld WF; Dutronc Y; Yu G; Ball SG; Somani N; Craiglow BG
JAMA Dermatol; 2023 Sep; 159(9):970-976. PubMed ID: 37556146
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
Wei D; Chen Y; Shen Y; Xie B; Song X
Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
[TBL] [Abstract][Full Text] [Related]
23. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
Mackay-Wiggan J; Jabbari A; Nguyen N; Cerise JE; Clark C; Ulerio G; Furniss M; Vaughan R; Christiano AM; Clynes R
JCI Insight; 2016 Sep; 1(15):e89790. PubMed ID: 27699253
[No Abstract] [Full Text] [Related]
24. Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta-analysis.
Husein-ElAhmed H; Husein-ElAhmed S
J Eur Acad Dermatol Venereol; 2024 May; 38(5):835-843. PubMed ID: 38279559
[TBL] [Abstract][Full Text] [Related]
25. [Janus kinase inhibitors for the treatment of alopecia areata].
Kobal I; Ramot Y
Hautarzt; 2022 May; 73(5):336-343. PubMed ID: 35482047
[TBL] [Abstract][Full Text] [Related]
26. The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients.
Mao MQ; Ding YX; Jing J; Tang ZW; Miao YJ; Yang XS; Chen YH; Chen SZ; Wu XJ; Lu ZF
Front Immunol; 2023; 14():1195858. PubMed ID: 37334349
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.
Zhao Y; Zhang L; Ding Y; Tao X; Ji C; Dong X; Lu J; Wu L; Wang R; Lu Q; Goh AH; Liu R; Zhang Z; Zhang J
Am J Clin Dermatol; 2021 Nov; 22(6):877-889. PubMed ID: 34374027
[TBL] [Abstract][Full Text] [Related]
28. Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis.
Barati Sedeh F; Michaelsdóttir TE; Henning MAS; Jemec GBE; Ibler KS
Acta Derm Venereol; 2023 Jan; 103():adv00855. PubMed ID: 36695751
[TBL] [Abstract][Full Text] [Related]
29. Janus kinase inhibitors for alopecia areata.
King BA; Craiglow BG
J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
[TBL] [Abstract][Full Text] [Related]
30. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
31. Baricitinib: A Review in Severe Alopecia Areata.
Fung S; Shirley M
Am J Clin Dermatol; 2023 Jul; 24(4):661-668. PubMed ID: 37326792
[TBL] [Abstract][Full Text] [Related]
32. The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double-blind placebo-controlled trial.
Rafati M; Mahmoudian R; Golpour M; Kazeminejad A; Saeedi M; Nekoukar Z
Dermatol Ther; 2022 Jun; 35(6):e15450. PubMed ID: 35289043
[TBL] [Abstract][Full Text] [Related]
33. Review of Baricitinib in the Treatment of Alopecia Areata.
Singh R; Driscoll MS
J Drugs Dermatol; 2023 Sep; 22(9):935-940. PubMed ID: 37683061
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of T-cell activity in alopecia areata: recent developments and new directions.
Passeron T; King B; Seneschal J; Steinhoff M; Jabbari A; Ohyama M; Tobin DJ; Randhawa S; Winkler A; Telliez JB; Martin D; Lejeune A
Front Immunol; 2023; 14():1243556. PubMed ID: 38022501
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial.
Tosti A; Iorizzo M; Botta GL; Milani M
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1243-7. PubMed ID: 17062039
[TBL] [Abstract][Full Text] [Related]
36. Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors.
Paggioli I; Moss J
J Autoimmun; 2022 Dec; 133():102926. PubMed ID: 36335798
[TBL] [Abstract][Full Text] [Related]
37. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
King B; Mostaghimi A; Shimomura Y; Zlotogorski A; Choi GS; Blume-Peytavi U; Passeron T; Holzwarth K; Dutronc Y; McCollam J; Yang FE; Stanley S; Wu WS; Sinclair R
Br J Dermatol; 2023 Feb; 188(2):218-227. PubMed ID: 36763878
[TBL] [Abstract][Full Text] [Related]
38. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
[TBL] [Abstract][Full Text] [Related]
39. Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety.
Lai VWY; Chen G; Gin D; Sinclair R
J Am Acad Dermatol; 2019 Sep; 81(3):694-701. PubMed ID: 31048013
[TBL] [Abstract][Full Text] [Related]
40. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
Stefanis AJ
Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]